Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report

Cellular Oncology

Volumn 39, Issue 3, 2016, Pages 287-293

  Karatzas, Demetrios N ^a   Xanthopoulos, Konstantinos ^a   Kotantaki, Panorea ^a   Pseftogas, Athanasios ^a   Teliousis, Konstantinos ^b   Hatzivassiliou, Eudoxia G ^b   Kontoyiannis, Dimitris L ^c   Poutahidis, Theofilos ^b   Mosialos, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Colon cancer; CYLD; JNK; NF B; Tumor suppressor

Indexed keywords

CYLD PROTEIN; DEUBIQUITINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE;

ADENOMATOUS POLYP; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME DELETION; COLITIS; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CONTROLLED STUDY; CYLD GENE; DISEASE EXACERBATION; GENE INACTIVATION; GENE MUTATION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; CARCINOGENESIS; COLORECTAL TUMOR; COMPLICATION; DISEASE MODEL; GENETICS; INTESTINE MUCOSA; PATHOLOGY;

ANIMALS; CARCINOGENESIS; COLITIS; COLORECTAL NEOPLASMS; CYSTEINE ENDOPEPTIDASES; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84962173697     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-016-0279-3     Document Type: Article

References (27)

1. G. R. Bignell, W. Warren, S. Seal, M. Takahashi, E. Rapley, R. Barfoot, H. Green, C. Brown, P. J. Biggs, S. R. Lakhani, C. Jones, J. Hansen, E. Blair, B. Hofmann, R. Siebert, G. Turner, D. G. Evans, C. Schrander-Stumpel, F. A. Beemer, A. van Den Ouweland, D. Halley, B. Delpech, M. G. Cleveland, I. Leigh, J. Leisti, S. Rasmussen, Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160–165 (2000)
2. J. J. Keats, R. Fonseca, M. Chesi, R. Schop, A. Baker, W. J. Chng, S. Van Wier, R. Tiedemann, C. X. Shi, M. Sebag, E. Braggio, T. Henry, Y. X. Zhu, H. Fogle, T. Price-Troska, G. Ahmann, C. Mancini, L. A. Brents, S. Kumar, P. Greipp, A. Dispenzieri, B. Bryant, G. Mulligan, L. Bruhn, M. Barrett, R. Valdez, J. Trent, A. K. Stewart, J. Carpten, P. L. Bergsagel, Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131–144 (2007)
3. C. M. Annunziata, R. E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, S. Dave, E. M. Hurt, B. Tan, H. Zhao, O. Stephens, M. Santra, D. R. Williams, L. Dang, B. Barlogie, J. D. Shaughnessy Jr., W. M. Kuehl, L. M. Staudt, Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007)
4. W. Wu, H. Zhu, Y. Fu, W. Shen, J. Xu, K. Miao, M. Hong, W. Xu, P. Liu, J. Li, Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia. Leuk. Lymphoma 55, 588–594 (2014)
5. R. Massoumi, S. Kuphal, C. Hellerbrand, B. Haas, P. Wild, T. Spruss, A. Pfeifer, R. Fassler, A. K. Bosserhoff, Down-regulation of CYLD expression by snail promotes tumor progression in malignant melanoma. J. Exp. Med. 206, 221–232 (2009)
6. C. Hellerbrand, E. Bumes, F. Bataille, W. Dietmaier, R. Massoumi, A. K. Bosserhoff, Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28, 21–27 (2007)
7. R. Massoumi, Ubiquitin chain cleavage: CYLD at work. Trends Biochem. Sci. 35, 392–399 (2010)
8. S. C. Sun, CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17, 25–34 (2010)
9. D. M. Moquin, T. McQuade, F. K. Chan, CYLD deubiquitinates RIP1 in the TNFalpha-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One 8, e76841 (2013)
10. A. Tsagaratou, E. Trompouki, S. Grammenoudi, D. L. Kontoyiannis, G. Mosialos, Thymocyte-specific truncation of the deubiquitinating domain of CYLD impairs positive selection in a NF-kappaB essential modulator-dependent manner. J. Immunol. 185, 2032–2043 (2010)
11. A. Tsagaratou, S. Grammenoudi, G. Mosialos, Differential requirement of IKKbeta for CYLD-dependent representation of thymic and peripheral T cell populations. Eur. J. Immunol. 41, 3054–3062 (2011)
12. K. Nikolaou, A. Tsagaratou, C. Eftychi, G. Kollias, G. Mosialos, I. Talianidis, Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and Cancer. Cancer Cell 21, 738–750 (2012)
13. I. Cleynen, E. Vazeille, M. Artieda, H. W. Verspaget, M. Szczypiorska, M. A. Bringer, P. L. Lakatos, F. Seibold, K. Parnell, R. K. Weersma, J. M. Mahachie John, R. Morgan-Walsh, D. Staelens, I. Arijs, G. De Hertogh, S. Muller, A. Tordai, D. W. Hommes, T. Ahmad, C. Wijmenga, S. Pender, P. Rutgeerts, K. Van Steen, D. Lottaz, S. Vermeire, A. Darfeuille-Michaud, Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut 63, 1265–1274 (2014)
14. C. M. Costello, N. Mah, R. Hasler, P. Rosenstiel, G. H. Waetzig, A. Hahn, T. Lu, Y. Gurbuz, S. Nikolaus, M. Albrecht, J. Hampe, R. Lucius, G. Kloppel, H. Eickhoff, H. Lehrach, T. Lengauer, S. Schreiber, Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2, e199 (2005)
15. J. Zhang, B. Stirling, S. T. Temmerman, C. A. Ma, I. J. Fuss, J. M. Derry, A. Jain, Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J. Clin. Invest. 116, 3042–3049 (2006)
16. E. Trompouki, A. Tsagaratou, S. K. Kosmidis, P. Dolle, J. Qian, D. L. Kontoyiannis, W. V. Cardoso, G. Mosialos, Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. Neoplasia 11, 469–476 (2009)
17. E. Karamanavi, K. Angelopoulou, S. Lavrentiadou, A. Tsingotjidou, Z. Abas, I. Taitzoglou, I. Vlemmas, S.E. Erdman and T. Poutahidis. Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl. Oncol. 7, 174–187 e175 (2014)
18. K. Vazquez-Santillan, J. Melendez-Zajgla, L. Jimenez-Hernandez, G. Martinez-Ruiz, V. Maldonado, NF-kappaB signaling in cancer stem cells: a promising therapeutic target? Cell. Oncol. 38, 327–339 (2015)
19. W. Zhou, J. Yuan, Necroptosis in health and diseases. Semin. Cell Dev. Biol. 35, 14–23 (2014)
20. P. S. Welz, A. Wullaert, K. Vlantis, V. Kondylis, V. Fernandez-Majada, M. Ermolaeva, P. Kirsch, A. Sterner-Kock, G. van Loo, M. Pasparakis, FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477, 330–334 (2011)
21. J. Niu, Y. Shi, K. Iwai, Z. H. Wu, LUBAC regulates NF-kappaB activation upon genotoxic stress by promoting linear ubiquitination of NEMO. Embo J 30, 3741–3753 (2011)
22. W.L. Yang, G. Jin, C.F. Li, Y.S. Jeong, A. Moten, D. Xu, Z. Feng, W. Chen, Z. Cai, B. Darnay, W. Gu and H.K. Lin. Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci. Signal. 6, ra3 (2013)
23. D. Takiuchi, H. Eguchi, H. Nagano, Y. Iwagami, Y. Tomimaru, H. Wada, K. Kawamoto, S. Kobayashi, S. Marubashi, M. Tanemura, M. Mori, Y. Doki, Involvement of microRNA-181b in the gemcitabine resistance of pancreatic cancer cells. Pancreatology 13, 517–523 (2013)
24. J. Terzic, S. Grivennikov, E. Karin and M. Karin. Inflammation and colon cancer. Gastroenterology 138, 2101–2114 e2105 (2010)
25. R. Massoumi, K. Chmielarska, K. Hennecke, A. Pfeifer, R. Fassler, Cyld inhibits tumor cell proliferation by blocking bcl-3-dependent NF-kappaB signaling. Cell 125, 665–677 (2006)
26. D. V. Tauriello, A. Haegebarth, I. Kuper, M. J. Edelmann, M. Henraat, M. R. Canninga-van Dijk, B. M. Kessler, H. Clevers, M. M. Maurice, Loss of the tumor suppressor CYLD enhances wnt/beta-catenin signaling through K63-linked ubiquitination of dvl. Mol. Cell 37, 607–619 (2010)
27. B. Sumithra, U. Saxena, A. B. Das, Alternative splicing within the wnt signaling pathway: role in cancer development. Cell. Oncol. 39, 1–13 (2016)